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BACKGROUND Low ﬂow, low gradient, aortic stenosis is becoming
increasingly recognized as a subgroup of severe aortic stenosis. Ac-
celeration time (AT) has been correlated with severity of severe aortic
stenosis (AS). We examined the epidemiology of Low ﬂow, low
gradient (LF/LG) severe AS and the correlation with AT to predict the
valve area.
METHODS We studied 138 consecutive patients diagnosed with se-
vere AS and normal ejection fraction (>55%) by echocardiography.
The mean age was 8110 yrs; 66% were females, 63% were African
Americans and 86% had hypertension. Chi square test was used for
comparing binary variables; student t-test for comparing means, and
linear regression was performed using IBM SPSS.
RESULTS 47 (34%) patients had stroke volume index < 35 and 28
(20%) had low ﬂow and low aortic mean gradient (<40 mmHg). There
were no signiﬁcant differences in gender and race distribution or past
medical history in the groups divided based on LF/LG. The aortic
valve area by continuity equation was 0.740.16 vs 0.730.14, nor
was there a difference in AVA index, dimensionless index or EF. Mean
gradient (4516 vs 27.57 mmHg), as did peak gradient (7323 vs
4812 mmHg), stroke volume index (42.410 vs 285 ml/m2), ZVA
(4.31.4 vs 5.41.8), average AT (11320 vs 9416 ms) and average
ejection time (31631 vs 29237 sec) were signiﬁcantly different (p
value <.01). AT signiﬁcantly and negatively correlated with AVA index
in both the LF/LG (r -0.368, p <.01), and rest of the cohort group (r
-0.414, p <.01). Adjusted for age, gender, race, and ejection fraction
using linear multivariate regression analysis, AT and LF/LG were
signiﬁcant predictors of AVA index.Parameter Coefﬁcient SE P Value(Constant) .603 .047Female .044 .017 <.01Acceleration time(AT) -1.913 .402 <.01LF/LG -.068 .021 <.01CONCLUSIONS Acceleration time is signiﬁcantly correlated with AVA
index derived from the continuity equation in both traditional severe
AS and in LF/LG severe AS, and is an independent predictor of AVA
index. The utility of AT in differentiating the severe from moderate AS
in LF/LG group needs to be evaluated.
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BACKGROUND A percutaneous approach with transcatheter aortic
valve replacement (TAVR) and percutaneous coronary intervention
(PCI) of the left main (LM) is frequently utilized in high-risk patients
with coexisting aortic stenosis and LM disease. Outcomes of TAVR
plus LM PCI (Figure 1A) have not been previously reported. The pri-
mary objective of the TAVR-LM registry is to evaluate the clinical
outcomes in patients undergoing TAVR plus LM PCI.
METHODS We retrospectively collected clinical, echocardiographic,
computed-tomographic and angiographic characteristics in 204 pa-
tients undergoing TAVR plus LM PCI. One-hundred twenty-eight
matched patient pairs were generated by performing 1:1 case-control
matching between 167 patients with pre-existing LM stent undergoing
TAVR and 1188 control patients undergoing TAVR without LM
revascularization.
RESULTS One-year mortality (9.4% vs. 10.2%, p ¼ 0.83) was similar
between the TAVR plus LM PCI cohort and matched controls
(Figure 1B). One-year mortality after TAVR plus LM PCI was not
different among patients with unprotected, compared to protected
LM (7.8% vs. 8.1%, p ¼ 0.88); among those with ostial versus non-
ostial LM stents (10.3% vs. 15.6%, p ¼ 0.20); and among those un-
dergoing LM PCI within 3 months, compared to those with LM PCI
greater than 3 months prior to TAVR (7.4% vs. 8.6%, p ¼ 0.61). Un-
planned LM PCI performed due to TAVR-related coronary complica-
tion, compared to planned LM PCI performed for pre-existing LM
disease, resulted in increased 30-day (15.8% vs. 3.4%, p ¼ 0.013) and 1-
year mortality (21.1% vs. 8.0%, p ¼ 0.071).
